Antibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-76985 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-76985, RRID:AB_11035814
- Product name
- Rabbit Polyclonal TRAILR4/TNFRSF10D/DcR2 Antibody
- Antibody type
- Polyclonal
- Description
- Peptide affinity purified.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway.
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by DJ-1 in thyroid cancer cells.
Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface.
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Gupta SC, Francis SK, Nair MS, Mo YY, Aggarwal BB
The Journal of biological chemistry 2013 Nov 8;288(45):32343-56
The Journal of biological chemistry 2013 Nov 8;288(45):32343-56
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y
Neuro-oncology 2010 Jul;12(7):687-700
Neuro-oncology 2010 Jul;12(7):687-700
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A
Blood 2008 Sep 15;112(6):2450-62
Blood 2008 Sep 15;112(6):2450-62
Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T, Sakai T
Cancer research 2008 Nov 1;68(21):8918-27
Cancer research 2008 Nov 1;68(21):8918-27
Regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by DJ-1 in thyroid cancer cells.
Zhang HY, Wang HQ, Liu HM, Guan Y, Du ZX
Endocrine-related cancer 2008 Jun;15(2):535-44
Endocrine-related cancer 2008 Jun;15(2):535-44
Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface.
Kawakubo T, Okamoto K, Iwata J, Shin M, Okamoto Y, Yasukochi A, Nakayama KI, Kadowaki T, Tsukuba T, Yamamoto K
Cancer research 2007 Nov 15;67(22):10869-78
Cancer research 2007 Nov 15;67(22):10869-78
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X, Yue P, Khuri FR, Sun SY
Cancer research 2005 Oct 15;65(20):9169-75
Cancer research 2005 Oct 15;65(20):9169-75
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades N
Investigative ophthalmology & visual science 2005 Jan;46(1):358-66
Investigative ophthalmology & visual science 2005 Jan;46(1):358-66
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL, Zou WY, Song LH, Wei W
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP
Blood 2002 Mar 15;99(6):2162-71
Blood 2002 Mar 15;99(6):2162-71
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S, Koike N, Adachi S
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N
The American journal of pathology 2002 Aug;161(2):643-54
The American journal of pathology 2002 Aug;161(2):643-54
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene 2002 Aug 22;21(37):5673-83
Oncogene 2002 Aug 22;21(37):5673-83
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N, Poulaki V, Mitsiades C, Tsokos M
Cancer research 2001 Mar 15;61(6):2704-12
Cancer research 2001 Mar 15;61(6):2704-12
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Basile JR, Zacny V, Münger K
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC
Blood 2001 Aug 1;98(3):795-804
Blood 2001 Aug 1;98(3):795-804
Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I
Cancer research 2000 Aug 1;60(15):4122-9
Cancer research 2000 Aug 1;60(15):4122-9
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: TRAILR4/TNFRSF10D/DcR2 Antibody [NBP1-76985] - Analysis of 50 ug of whole cell lysate from HeLa cells with anti-DcR2 at 1:1000 dilution.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: TRAILR4/TNFRSF10D/DcR2 Antibody [NBP1-76985] - Analysis of DcR2 in mouse kidney node tissue with DcR2 antibody at 2.5 ug/ml.